Obesity, Abdominal
Conditions
Keywords
probiotics, visceral fat, abdominal obesity
Brief summary
The finding that the combination of the inactivated probiotic Bifidobacterium Lactis (BPL1), inulin as a source of soluble fiber and omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in a surimi matrix has positive effects on visceral adiposity , insulin resistance and plasma tryclycerides in a preclinical model of rats that present obesity induced by diet is the basis of the present hypothesis. This finding is based on the fact that these three bioactive compounds exert these effects through sensibly different and complementary mechanisms, which suggests that their combined use may have synergistic effects. On this basis the present hypothesis is posed: the consumption of surimi enriched with inactivated probiotic BPL1, inulin and omega-3 fatty acids, in the same doses that have been effective in obese rats (SIAP), can induce a reduction of more than 5% of visceral adipose tissue, being clinically relevant in people with abdominal obesity. If the effect on abdominal obesity is associated or not with a lower glycemia and / or absorption of fats induced by the consumption of surimi can be evaluated by monitoring these parameters for 4 hours after the ingestion of a breakfast high in fat. The main objective of this study was to evaluate the effects of the consumption of surimi enriched with the probiotic BPL1, inulin and omega-3 fatty acids, on visceral abdominal adiposity in people with abdominal obesity.
Interventions
COMBINATION_PRODUCTSurimi intervention
The bioactive compounds used to obtain the surimi product are: * Inulin (3.4 grams per 100 grams of surimi, 1.7 grams per 50 grams of surimi): Obtained from Chicory originating in Europe. * EPA + DHA (740 mg per 100 g of surimi, therefore 370 mg per 50 g): Obtained from sardine and anchovy fish oil, encapsulated in tilapia gelatine, originating in the United States. * Probiotic BPL1 It was a 3 months nutritional intervention. Volunteers will eat 50g per day of enriched surimi.
COMBINATION_PRODUCTPlacebo
Conventional surimi It was a 3 months nutritional intervention. Volunteers will eat 50g per day of conventional surimi.
Sponsors
Technological Centre of Nutrition and Health, Spain
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Men and women over 18 years of age with a waist circumference ≥102 cm in men and ≥88 cm in women. 2. Sign the informed consent.
Exclusion criteria
1. Having any condition incompatible with nuclear magnetic resonance (RNM) tests, such as metallic implants or sensitive to magnetic fields, pacemakers or suffering from claustrophobia. 2. Having diabetes (glucose ≥ 126 mg / dL). 3. BMI values ≥ 40 kg / m2 4. Waist circumference\> 150 cm. 5. Present dyslipidemia (LDL cholesterol ≥ 189 mg / dL and / or triglycerides ≥ 350 mg / dL). 6. Take supplements or multivitamin supplements or phytotherapeutic products that interfere with the treatment under study. 7. Present chronic alcoholism. 8. Present some chronic gastrointestinal disease. 9. Present intolerances and / or food allergies related to the study product. 10. Presenting anemia (hemoglobin ≤13 g / dL in men and ≤12 g / dL in women) 11. Present some chronic disease in clinical manifestation. 12. Being pregnant or intending to become pregnant. 13. Be in breastfeeding period. 14. Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days prior to inclusion in the study. 15. Follow a hypocaloric diet and / or pharmacological treatment for weight loss. 16. Suffer eating disorders. 17. Being unable to follow the study guidelines.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in abdominal visceral fat (measured in mm2) | 12 weeks, week 1 and week 12 | measured by magnetic resonance imaging (MRI), transverse body scan in one axial slice 5 cm over L5-S1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in parameters of body composition (height, measured in meters) | 12 weeks, week 1 | Trained dieticians measure height using a well mounted stadiometer (Tanita Leicester Portable; Tanita Corp., Barcelona, Spain) |
| Changes in parameters of body composition (BMI) | 12 weeks, week 1 and week 12 | Body mass index (BMI) is calculated as the ratio between measured weight (kg)/and the square of height (m). |
| Changes in parameters of body composition (weight, measured in kg) | 12 weeks, week 1 and week 12 | Trained dieticians measure weight using a body composition analyzer (Tanita SC 330-S; Tanita Corp., Barcelona, Spain). |
| Changes in blood pressure (measured in mmHg) | 12 weeks, week 1 and week 12 | Systolic and diastolic blood pressure (SBP and DBP) are measured twice after 2-5 minutes of patient respite, seated, with one-minute interval in between, using an automatic sphygmomanometer (OMRON HEM-907; Peroxfarma, Barcelona, Spain). |
| Changes in plasmatic parameters (glucose, total cholesterol, LDL and HDL cholesterol, triglycerides, non-esterified fatty acids, Apo B100, Apo A1 and Insulin, measured in mg/dL) | 12 weeks, week 1 and week 12 | Serum lipids and apolipoproteins, non-esterified fatty acids, glucose, and insulin concentrations are measured in serum by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland). LDL-c is calculated by the Friedewald formula. |
| Changes in parameters of body composition (waist circumference, measured in centimeters) | 12 weeks, week 1 and week 12 | Waist circumference (WC) is measured at the umbilicus using a 150 cm anthropometric steel measuring tape. |
Countries
Spain
Outcome results
None listed